Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Trials

NCT07824973

ClinicalTrials.gov

Trial ID
T-ctgov-NCT07824973
Registry
ClinicalTrials.gov
NCT number
NCT07824973
Sponsor, as registered
Valdemar Landgren
Phase
NA
Indication
Treatment Resistant Depression (TRD)
Status
NOT_YET_RECRUITING
Start date
2026-09
Primary completion
2029-12
Registered countries
Sweden
Sites
1

The sponsor's registered location list, which states intent rather than approval.

clinicaltrials.govctgov registryverified 2026-09-22

Notes on the record

Fields read from the ClinicalTrials.gov v2 API record on 2026-09-22. countries is the distinct country list across all registered locations; site_count is the number of location entries. Added because Issue 15's Europe section relies on this record and it had no row: the issue was drafted before the row existed, which is DATA LAYER rule 1 the wrong way round, corrected here rather than left. Academic sponsor, not industry.

Cited in

Issues quoting NCT07824973 in their own text.